Chanca Piedra
Amazonian "stone breaker" herb taken for kidney stones and liver health.
What is Chanca Piedra?
Chanca Piedra (Phyllanthus niruri) is a gut and immune supplement used for support stone-free outcomes after lithotripsy. NutriDex grades the human evidence as Preliminary. Chanca piedra ("stone breaker") is a tropical herb long used in South America and Ayurveda for kidney stones and liver complaints. The human evidence is thin but not empty. A randomized trial found it normalized high urinary calcium in stone formers, and a controlled study reported higher stone-free rates after shock-wave lithotripsy, especially for lower-pole stones (93.7% vs 70.8%). A 2020 meta-analysis of just two studies found small reductions in stone size and number, and a 2025 systematic review concluded it appears safe but with mixed efficacy. A 2023 year-long RCT in fatty-liver patients showed a modest improvement in liver-stiffness (fibrosis) score but no change in liver enzymes or metabolic markers. For chronic hepatitis B, Cochrane reviews found no convincing benefit. Most trials are small, short, and at high risk of bias, so claims remain unproven.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Stone-free rate after shock-wave lithotripsyOne RCT showed higher lower-pole stone clearance (93.7% vs 70.8%), but a systematic review calls efficacy mixed and trials high-bias. | Preliminary | ↑ benefit · moderate | 2 |
| Lower elevated urinary calcium in stone formersSingle RCT (n=69) reduced urinary calcium in hypercalciuric patients but did not improve stone passage overall. | Preliminary | ↑ benefit · small | 1 |
| Reduce kidney stone size and numberMeta-analysis of only 2 controlled studies found small reductions (SMD ~-0.38); authors call efficacy modest and pending. | Preliminary | ↔ mixed · small | 2 |
| Liver fibrosis/stiffness in NAFLD12-month RCT (n=226) improved liver-stiffness score but showed no change in liver enzymes or metabolic markers. | Preliminary | ↔ mixed · small | 1 |
| Chronic hepatitis B viral controlCochrane review and a separate RCT found no significant seroconversion or viral-load change; trials at high risk of bias. | Moderate | — no effect · negligible | 2 |